EXEL Stock — Exelixis Inc.

Exelixis Inc. (EXEL)

Updated October 16, 2026.

EXEL is a Stock. Total return is 309.7% over the past 26.5 years, 400.2 points behind SPY at 709.9%.

Exelixis is an oncology company focused on discovering, developing, and commercializing medicines for difficult-to-treat cancers. The company markets CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan, while advancing a pipeline of novel therapeutics including antibody-drug conjugates and bispecific antibodies through collaborations with major pharmaceutical partners. The company does not currently distribute to shareholders.

EXEL performance versus SPY

Price and return data through 2026-10-16.

Total return is 309.7% over the past 26.5 years, 400.2 points behind SPY at 709.9%. Over the past year its total return — price change plus distributions reinvested — is 58.7%. Its deepest 1-year drawdown was 12.6%.

EXEL key facts

Asset type

Stock

Asset class

Equity

Inception date

04/11/2000

Distribution frequency

None

Last close

$62.23 (as of 2026-10-16)

Market cap

$15,419,454,693

Average volume

2637281.0

Beta

0.466

Payout ratio

0.0%

P/E ratio

19.15

Forward P/E

13.5501

EPS

$3.25

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EXEL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 12.6%.

Who may consider EXEL — and who may not

It is a weaker fit for investors who need monthly cash flow (EXEL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EXEL

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions